Journal of Applied Physiology AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 101: 1085-1090, 2006. First published June 15, 2006; doi:10.1152/japplphysiol.00332.2006
8750-7587/06 $8.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
101/4/1085    most recent
00332.2006v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fesler, P.
Right arrow Articles by Naeije, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fesler, P.
Right arrow Articles by Naeije, R.

Effects of sildenafil on hypoxic pulmonary vascular function in dogs

Pierre Fesler,1 Alberto Pagnamenta,2 Benoit Rondelet,2 François Kerbaul,2 and Robert Naeije2

1Department of Internal Medicine, Hôpital Lapeyronie, Montpellier, France; and 2Laboratory of Physiology, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium

Submitted 20 March 2006 ; accepted in final form 29 May 2006

Sildenafil has been shown to be an effective treatment of pulmonary arterial hypertension and is believed to present with pulmonary selectivity. This study was designed to determine the site of action of sildenafil compared with inhaled nitric oxide (NO) and intravenous sodium nitroprusside (SNP), known as selective and nonselective pulmonary vasodilators, respectively. Inhaled NO (40 ppm), and maximum tolerated doses of intravenous SNP and sildenafil, (5 µg·kg–1·min–1 and 0.1 mg·kg–1·h–1), respectively, were administered to eight dogs ventilated in hypoxia. Pulmonary vascular resistance (PVR) was evaluated by pulmonary arterial pressure (Ppa) minus left atrial pressure (Pla) vs. flow curves, and partitioned into arterial and venous segments by the occlusion method. Right ventricular hydraulic load was defined by pulmonary arterial characteristic impedance (Zc) and elastance (Ea) calculations. Right ventricular arterial coupling was estimated by the ratio of end-systolic elastance (Ees) to Ea. Decreasing the inspired oxygen fraction from 0.4 to 0.1 increased Ppa – Pla at a standardized flow of 3 l·min–1·m–2 from 6 ± 1 to 18 ± 1 mmHg (mean ± SE). Ppa – Pla was decreased to 9 ± 1 by inhaled NO, 14 ± 1 by SNP, and 14 ± 1 mmHg by sildenafil. The partition of PVR, Zc, Ea, and Ees/Ea was not affected by the three interventions. Inhaled NO did not affect systemic arterial pressure, which was similarly decreased by sildenafil and SNP, from 115 ± 4 to 101 ± 4 and 98 ± 5 mmHg, respectively. We conclude that inhaled NO inhibits hypoxic pulmonary vasoconstriction more effectively than sildenafil or SNP, and sildenafil shows no more selectivity for the pulmonary circulation than SNP.

pulmonary hypertension; nitric oxide; sodium nitroprusside; right ventricle; pulmonary vascular resistance; pulmonary vascular impedance



Address for reprint requests and other correspondence: R. Naeije, Laboratory of Physiology, CP 604, 808 Lennik Rd., B-1070 Brussels, Belgium (e-mail: rnaeije{at}ulb.ac.be)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.